EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan
New indication concerns the treatment of patients with advanced HR-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting